Skip to main content
SpringerLink
Log in

Mitogen-Activated Protein Kinase (MAPK) Signaling

  • Chapter
  • First Online:
Predictive Biomarkers in Oncology

Abstract

The mitogen-activated protein kinases (MAPKs) have been under careful investigation for a long period, and this signaling pathway is one of the most studied. MAPKs regulate cell proliferation, gene expression, differentiation, mitosis, cell survival, and apoptosis. The mitogen-activated protein/extracellular signal-regulated kinase (MAPK/ERK) pathways are a cascade of signaling enzymes starting with the transmission of a signal from a receptor tyrosine kinase (RTK) located on the cell surface to the nucleus and ending in the regulation of transcription of target genes. Due to its importance in human cancers, MAPK/ERK signaling pathways are attractive targets for cancer drug development. In this chapter, we will present the MAPK signaling pathway and outline the function of the most relevant protein mediators that facilitate signaling. We will also highlight negative regulators of the pathway, drugs designed to block signaling, and ongoing clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Avruch J. MAP kinase pathways: the first twenty years. Biochim Biophys Acta. 2007;1773(8):1150–60.

    Article  CAS  PubMed  Google Scholar 

  2. Escos A, et al. p38gamma and p38delta mitogen activated protein kinases (MAPKs), new stars in the MAPK galaxy. Front Cell Dev Biol. 2016;4:31.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Dhillon AS, et al. MAP kinase signalling pathways in cancer. Oncogene. 2007;26(22):3279–90.

    Article  CAS  PubMed  Google Scholar 

  4. Burotto M, et al. The MAPK pathway across different malignancies: a new perspective. Cancer. 2014;120(22):3446–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Rauch N, et al. MAPK kinase signalling dynamics regulate cell fate decisions and drug resistance. Curr Opin Struct Biol. 2016;41:151–8.

    Article  CAS  PubMed  Google Scholar 

  6. Segal RA, Greenberg ME. Intracellular signaling pathways activated by neurotrophic factors. Annu Rev Neurosci. 1996;19:463–89.

    Article  CAS  PubMed  Google Scholar 

  7. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9(8):537–49.

    Article  CAS  PubMed  Google Scholar 

  8. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer. 2004;4(12):937–47.

    Article  CAS  PubMed  Google Scholar 

  9. Yan C, Theodorescu D. RAL GTPases: biology and potential as therapeutic targets in cancer. Pharmacol Rev. 2018;70(1):1–11.

    Article  PubMed  Google Scholar 

  10. Lal R, et al. Reovirus: rationale and clinical trial update. Curr Opin Mol Ther. 2009;11(5):532–9.

    CAS  PubMed  Google Scholar 

  11. Thirukkumaran C, Morris DG. Oncolytic viral therapy using reovirus. Methods Mol Biol. 2009;542:607–34.

    Article  CAS  PubMed  Google Scholar 

  12. Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol. 2004;5(11):875–85.

    Article  CAS  PubMed  Google Scholar 

  13. Forbes SA, et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2011;39(Database issue):D945–50.

    Article  CAS  PubMed  Google Scholar 

  14. Mirza AM, et al. Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT. Mol Cell Biol. 2004;24(24):10868–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Bulavin DV, Fornace AJ Jr. p38 MAP kinase’s emerging role as a tumor suppressor. Adv Cancer Res. 2004;92:95–118.

    Article  CAS  PubMed  Google Scholar 

  16. Cicenas J, et al. JNK, p38, ERK, and SGK1 inhibitors in cancer. Cancers (Basel). 2017; 10(1).

    Article  PubMed Central  Google Scholar 

  17. Cunningham SC, et al. Targeted deletion of MKK4 in cancer cells: a detrimental phenotype manifests as decreased experimental metastasis and suggests a counterweight to the evolution of tumor-suppressor loss. Cancer Res. 2006;66(11):5560–4.

    Article  CAS  PubMed  Google Scholar 

  18. Krishnan V, et al. Using MKK4’s metastasis suppressor function to identify and dissect cancer cell-microenvironment interactions during metastatic colonization. Cancer Metastasis Rev. 2012;31(3–4):605–13.

    Article  CAS  PubMed  Google Scholar 

  19. Zhao Y, Adjei AA. The clinical development of MEK inhibitors. Nat Rev Clin Oncol. 2014;11:385–400.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncology Research Institute, Loyola University Medical Center, Maywood, IL, USA

    Andrei Zlobin

  2. Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL, USA

    Jeffrey C. Bloodworth

  3. Department of Microbiology and Immunology, Stritch School of Medicine, Cardinal Bernardin Cancer Center of Loyola University Chicago, Maywood, IL, USA

    Clodia Osipo

Authors
  1. Andrei Zlobin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey C. Bloodworth
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Clodia Osipo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Clodia Osipo .

Editor information

Editors and Affiliations

  1. Department of Pathology and Lab Medicine, Indiana University School of Medicine, Indianapolis, IN, USA

    Sunil Badve

  2. Targos Inc., Issaquah, WA, USA

    George Louis Kumar

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Zlobin, A., Bloodworth, J.C., Osipo, C. (2019). Mitogen-Activated Protein Kinase (MAPK) Signaling. In: Badve, S., Kumar, G. (eds) Predictive Biomarkers in Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-95228-4_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-95228-4_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-95227-7

  • Online ISBN: 978-3-319-95228-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation